MacroGenics | MGNX - Gross Profit On Sales


MacroGenics reported $31.11M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Amgen USD 6.89B 415M Dec/2025
AstraZeneca USD 12.61B 225M Mar/2026
Biogen USD 1.82B 169.5M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Genmab DKK 977M 13M Dec/2025
Geron USD 50.14M 3.44M Mar/2026
Gilead Sciences USD 5.52B 791M Mar/2026
J&J USD 17.24B 642M Mar/2026
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
MacroGenics USD 31.11M 30.14M Dec/2025
Merck USD 10.85B 2.57B Dec/2025
Pfizer USD 11.04B 1.24B Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Xencor USD 21M 22.61M Sep/2025